在急性心力衰竭患者中,梅托拉与西亚相比,尿素抵抗和功能障碍:一项回顾性队列研究
Caitlin M Gibson1,2, Meghan M Beard2, Alisa K Escano1,3
1Virginia Commonwealth University School of Pharmacy, Richmond, VA.
Journal of cardiovascular pharmacology
|August 8, 2024
概括
在急性心力衰竭和功能障碍的患者中,罗胺的利尿疗效比美托拉更大,增加尿量而不恶化功能或电解质,除了低磁性血症.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- 建议在急性心力衰竭 (AHF) 与体积过载时使用静脉循环利尿剂.
- 对于选择用于循环利尿剂耐药性的额外利尿剂存在有限的指导.
- 患有AHF和功能障碍 (eGFR<45mL/min/1.73m2) 的患者往往需要加强尿路.
研究的目的:
- 在患有功能障碍的AHF患者中,比较罗亚胺与美托拉的利尿疗效和安全性.
- 评估这些 thiazide 剂对 24 小时尿量和功能的影响.
主要方法:
- 在221名住院患有功能障碍的AHF患者中进行了多中心,回顾性队列研究.
- 患者除了静脉注射循环利尿剂外,还接受了罗亚或美托拉.
- 主要终点:24小时尿量变化;次要终点:体重变化,血管压缩剂使用,电解质异常,功能.
主要成果:
- 与甲 (平均7毫克) 相比,西 (平均632毫克) 导致24小时尿量显著增加 (P < 0.001).
- 甲治疗与72小时后血清肌素的统计显著降低有关 (P = 0.016).
- 随着甲的使用,出现了更多的低磁性血症;在其他电解质或体重变化中没有观察到群体之间的显著差异.
结论:
- 在循环中,与甲索拉相比,罗提亚齐德显示出更高的利尿疗效,具有功能障碍的抗利尿药耐药AHF患者.
- thiazide 没有增加或血清肌氨酸乱,但与增加的低血症有关.
- 需要进行前性研究来证实这些关于利尿剂反应和安全性的发现.
相关概念视频
01:22Heart Failure Drugs: Diuretics
353
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
353
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
573
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
573
01:22Heart Failure Drugs: β-Blockers
326
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:11Renal Failure: Dose Adjustments
77
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
77